Quince Therapeutics (QNCX) Projected to Post Earnings on Monday

Quince Therapeutics (NASDAQ:QNCX) is projected to announce its earnings results on Monday, March 24th. Analysts expect the company to announce earnings of ($0.18) per share for the quarter.

Quince Therapeutics Price Performance

Quince Therapeutics stock opened at $1.38 on Friday. Quince Therapeutics has a one year low of $0.51 and a one year high of $2.45. The business has a fifty day moving average price of $1.50 and a 200-day moving average price of $1.42. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53. The firm has a market capitalization of $60.72 million, a P/E ratio of -1.11 and a beta of 0.71.

Analysts Set New Price Targets

A number of equities analysts have recently commented on QNCX shares. D. Boral Capital reaffirmed a “buy” rating and issued a $12.00 price target on shares of Quince Therapeutics in a report on Wednesday, February 5th. Brookline Capital Management began coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price objective on the stock. Four analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, Quince Therapeutics currently has an average rating of “Buy” and an average target price of $9.50.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.